# Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical is an other based in Novato, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Novato, United States
- **Region:** North America
- **Address:** 60 Leveroni Court, Novato, CA 94949, United States
- **Assets under management:** Undisclosed
- **Website:** ultragenyx.com
- **LinkedIn:** https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-

## Regulatory record

- **Reports private funds:** No

## About

Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.

## Sectors

- Biotechnology
- Pharmaceuticals

## Offices

- Somerville, MA, United States
- Bedford, MA, United States
- Woburn, MA, United States
- South San Francisco, CA, United States
- Basel, Switzerland
- Paris, France
- Berlin, Germany
- Milan, Italy
- Schiphol, Netherlands
- Madrid, Spain
- Zurich, Switzerland
- Miami, FL, United States
- Olivos, Argentina
- São Paulo, Brazil
- Bogotá, Colombia
- Mexico City, Mexico
- Tokyo, Japan

## People

- Emil D. Kakkis — Chief Executive Officer and President

## Questions

### Who runs investment decisions at Ultragenyx?

Ultragenyx is a commercial-stage biopharmaceutical company, not an investment firm. Corporate strategy and capital allocation decisions are led by CEO and President Emil D. Kakkis, M.D., Ph.D., who founded the company. As a publicly traded enterprise, material investment and pipeline decisions are disclosed through SEC filings and Nasdaq announcements.

### What investment stages does Ultragenyx typically target?

Ultragenyx is not an allocator deploying into funds or external startups. It invests directly into its own clinical pipeline, moving programs from research through clinical development, regulatory approval, and commercial launch. The firm's pipeline covers assets at various stages, from preclinical gene therapy research to marketed products supported by its UltraCare access program.

### Which sectors does Ultragenyx explicitly avoid?

Ultragenyx focuses exclusively on rare and ultra-rare genetic diseases. Its public disclosures do not indicate activity in common disease indications, oncology, vaccines, or medical devices. The firm's patient support infrastructure, UltraCare, is built specifically for rare disease communities with conditions that often lack any approved treatment.

## Related profiles

- [Inferno Capital Group](https://altss.com/profile/inferno-capital-group)
- [VIC Technology Venture Development](https://altss.com/profile/vic-technology-venture-development)

---

Last updated: 2026-07-09T00:34:10.883Z

Canonical page: https://altss.com/profile/ultragenyx-pharmaceutical-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology